Protein Summary
DNA polymerase specifically involved in the DNA repair by translesion synthesis (TLS) (PubMed:10385124, PubMed:11743006, PubMed:24449906). Due to low processivity on both damaged and normal DNA, cooperates with the heterotetrameric (REV3L, REV7, POLD2 and POLD3) POLZ complex for complete bypass of DNA lesions. Inserts one or 2 nucleotide(s) opposite the lesion, the primer is further extended by the tetrameric POLZ complex. In the case of 1,2-intrastrand d(GpG)-cisplatin cross-link, inserts dCTP opposite the 3' guanine (PubMed:24449906). Particularly important for the repair of UV-induced pyrimidine dimers (PubMed:10385124, PubMed:11743006). Although inserts the correct base, may cause base transitions and transversions depending upon the context. May play a role in hypermutation at immunoglobulin genes (PubMed:11376341, PubMed:14734526). Forms a Schiff base with 5'-deoxyribose phosphate at abasic sites, but does not have any lyase activity, preventing the release of the 5'-deoxyribose ...more
- ENST00000372226
- ENSP00000361300
- ENSG00000170734
- ENST00000372236
- ENSP00000361310
- RAD30
- RAD30A
- XPV
- XPV
- XP-V
- RAD30
- RAD30A
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
---|---|---|---|
virus perturbation | 0.98 | ||
histone modification site profile | 0.91 | ||
kinase perturbation | 0.88 | ||
ligand (protein) perturbation | 0.83 | ||
small molecule perturbation | 0.79 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 230.3 (req: < 5)
Gene RIFs: 143 (req: <= 3)
Antibodies: 182 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 230.3 (req: >= 5)
Gene RIFs: 143 (req: > 3)
Antibodies: 182 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 14
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 2
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0